Kintara Therapeutics Inc (KTRA)

[jssdmm]

I complete agree. The management team is steadily moving forward (not even slow and steady as the trials do not require many participants, nor are they as lengthy as many trials) and consistently hitting their marks.

The clinical trial you speak of is set up nicely as well, as inclusion criteria requires a high level of mgmt in the tumor of patients. That means we are stacking the deck in our favor as many drugs are resistant here whereas this is the sweet spot for val-083. The next phase could certainly establish val-083 as the standard of care to be used in combination with other treatments.

https://clinicaltrials.gov/ct2/show/NCT02717962

Orphan status for ovarian cancer is icing on the cake. Very impressive.